Evidence map›Paper›PMID 42032630›Full record

ArticleJournal of nanobiotechnology2026

Layer-by-layer engineered outer membrane vesicles enable oral upadacitinib delivery for inflammation control and fibrosis attenuation in ulcerative colitis.

Ruoxue Dai, Shuang Che, Ying Shi, Siqi Zhang, Yin He, Jiaxin Yuan, Xi Xu, Junjie Zeng, Jifeng Chen, Changzheng Shi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ruoxue Dai *The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Department of Radiology and Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Shuang Che *The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Department of Radiology and Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Ying Shi *The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Department of Radiology and Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Siqi ZhangThe Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Department of Radiology and Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Yin HeThe Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Department of Radiology and Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Jiaxin YuanThe Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Department of Radiology and Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Xi XuThe Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Department of Radiology and Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Junjie ZengDepartment of Radiology and Nuclear Medicine, The Fifth Affiliated Hospital of Jinan University (Shenhe People's Hospital), Heyuan, 517000, China.
Jifeng ChenThe Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Department of Radiology and Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Changzheng ShiThe Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Department of Radiology and Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Yangzhi HuDepartment of Gastrointestinal Surgery, The Affiliated Hospital of Xiangnan University, Chenzhou, 423000, China. dehyz@xnu.edu.cn.
Jingge YangThe Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Department of Radiology and Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China. jdfy_yangjg@163.com.
Liangping LuoDepartment of Radiology and Nuclear Medicine, The Fifth Affiliated Hospital of Jinan University (Shenhe People's Hospital), Heyuan, 517000, China. tluolp@jnu.edu.cn.
Zeyu XiaoThe Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Department of Radiology and Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China. zeyuxiao@jnu.edu.cn.

Funding

the First Affiliated Hospital of Jinan University JNU1AF-CFTP-2022-a01233the Guangdong Basic and Applied Basic Research Foundation 2023A1515012660, 2022A1515220159, 2024A03J0231 and 2023A1515220128the Guangdong Special Support Program for Young Top-Notch Talents No. 2024TQ08Y995the Guangzhou Science and Technology Plan Project 2023A03J1037 and 2024A03J1118the Hunan Provincial Natural Science Foundation of China 2023JJ50067the National Natural Science Foundation of China 82271943
6 · The paper itself

Abstract

Ulcerative colitis (UC) is characterized by intertwined defects in the epithelial barrier, microbiota composition, and immune signaling, which collectively sustain inflammation and drive fibrosis. Here, we report a multifunctional oral nanoplatform OMV-LbL@Upa (OUL), comprising probiotic-derived outer membrane vesicles (OMVs) encapsulating the JAK-STAT inhibitor upadacitinib (Upa), further functionalized with a trans-cinnamic acid/chitosan-based layer-by-layer (LbL) coating. The LbL architecture significantly enhanced gastric stability and intestinal retention, enabling colon-targeted release while preserving OMV bioactivity. In both acute and chronic UC models, OUL significantly improved disease activity, restored tight junction proteins, corrected intestinal permeability, rebalanced gut microbiota, and reprogrammed macrophage polarization. Mechanistically, OUL suppressed JAK-STAT signaling pathways, culminating in attenuated collagen deposition and the downregulation of pro-fibrotic markers (α-SMA and vimentin). With no overt systemic toxicity observed, this orally administered nanoplatform integrates microbiota/epithelial restoration with targeted JAK1 inhibition to achieve anti-inflammatory and anti-fibrotic benefits, offering a clinically promising strategy for the management of UC.

Indexed as

Colitis, UlcerativeHeterocyclic Compounds, 3-RingInflammationAdministration, OralAnimalsAnti-Inflammatory AgentsColonFibrosisGastrointestinal MicrobiomeHumansMaleMiceMice, Inbred C57BLAnti-Inflammatory AgentsHeterocyclic Compounds, 3-RingIntestinal fibrosisLayer-by-layer assemblyOral drug deliveryOuter membrane vesiclesUlcerative colitisUpadacitinib

Identifiers

PMID42032630
PMCPMC13255370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.